Further research is warranted to clarify aberrant GFRAL expression in tumour tissues and the immunomodulatory effects of the GFRAL antagonists via neural pathways and direct effects on tumour cells, compared to anti-GDF-15 treatment. This evidence concerns the gene GFRAL and neoplasm.